ReAlta Life Sciences
NORFOLK, VA · Biotechnology, Healthcare · 31 employees
ReAlta Life Sciences is a clinical-stage biotech company dedicated to saving lives by rebalancing the inflammatory response to address life threatening acute inflammatory and rare diseases. ReAlta’s EPICC peptides are based on research into the human astrovirus, HAstV-1, which causes a non-inflammatory, self-limiting gastroenteritis unique among viruses by inhibiting components of the innate immun
Funding history
- Funding Round — $40.0M — Apr 2026
- Funding Round — $12.0M — May 2025
- Funding Round — $29.9M — May 2025
- Funding Round — $25.0M — May 2025
- Funding Round — $22.5M — Sep 2023
Recent signals
- Apr 08, 2026: Raised $40.0M
- Mar 24, 2026: ReAlta Life Sciences Appoints Howard Berman as CEO and Kia Motesharei as COO
- Jul 28, 2025: ReAlta Life Sciences Appoints Ellen Lubman as Chief Business Officer
- May 21, 2025: Raised $12.0M
- May 21, 2025: Raised $29.9M
- May 21, 2025: Raised $25.0M
- Dec 08, 2024: Launched ReAlta Life Sciences Reveals Positive Preclinical Data for RLS-0071 in Treating Acute Graft-Versus-Host Disease.
- Sep 04, 2024: ReAlta Life Sciences Appoints Peter Ho, Ph.D., as Head of Business Development and Corporate Strategy
See plans & pricing → Track ReAlta Life Sciences’s funding, hiring, and signals — with verified contacts — on Fundz.